Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 702-706

  Cibas, Edmund S ^a   Hong, Xuefei ^a   Crum, Christopher P ^a   Feldman, Sarah ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer screening; Cervical cancer; Cytology; Human papillomavirus; Pap test

Indexed keywords

VIRUS DNA;

ADULT; AGE DISTRIBUTION; ARTICLE; COMPUTER ANALYSIS; CONFIDENCE INTERVAL; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; AGE FACTORS; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33846975794     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.048     Document Type: Article

References (32)

1. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 (2002) 342-362
2. Cervical Cytology Screening. ACOG Practice Bulletin No. 45. American College of Obstetricians and Gynecologists. Obstet. Gynecol. 102 (2003) 417-427
3. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 95 (2003) 46-52
4. Herrero R., Hildesheim A., Bratti C., et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J. Natl. Cancer Inst. 92 (2000) 464-474
5. Hopman E.H., Rozendaal L., Voorhorst F.J., Walboomers J.M., Kenemans P., and Helmerhorst T.J. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. Br. J. Obstet. Gynecol. 107 5 (2000) 600-604
6. Jacobs M., WalBoomers J., Snijders P., et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int. J. Cancer 87 (2000) 221-227
7. Sellors J.W., Mahony J.B., Kaczorowski J., et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ 163 (2000) 503-508
8. Clavel C., Masure M., Bory J.-P., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 89 12 (2001) 1616-1623
9. Lazcano-Ponce E., Herrero R., Munoz N., et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int. J. Cancer 91 (2001) 412-420
10. Zuna R.E., Moore W., and Dunn S.T. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor. Mod. Pathol. 14 3 (2001) 147-151
11. Kulasingam S.L., Hughes J.P., Kiviat N.B., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. JAMA 288 (2002) 1749-1757
12. Molano M., Posso H., Weiderpass E., et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br. J. Cancer 87 (2002) 324-333
13. Petry K.-.U., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer 88 (2003) 1570-1577
14. de Sanjose S., Almirall R., Lloveras B., et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex. Transm. Dis. 30 (2003) 788-793
15. Arora R., Kumar A., Prusty B.K., Kailash U., Batra S., and Das B.C. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur. J. Obstet. Gynecol. Reprod. Biol. 121 (2005) 104-109
16. Hoyer H., Scheungraber C., Kuehne-Heid R., et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int. J. Cancer 116 (2005) 136-143
17. Evans M.F., Adamson C.S.-.C., Papillo J.L., St. John T.L., Leiman G., and Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 106 (2006) 1054-1064
18. Austin R.M., and Ramzy I. Increased detection of epithelial cell abnormalities of liquid-based gynecologic cytology preparations: a review of accumulated data. Acta Cytol. 42 (1998) 178-184
19. Weintraub J., and Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn. Cytopathol. 22 (2000) 52-59
20. Berstein S.J., Sanchez-Ramos L., and Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am. J. Obstet. Gynecol. 185 (2001) 308-317
21. Abulafia O., Pezzullo J.C., and Shere D.M. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol. Oncol. 90 (2003) 137-144
22. Biscotti C.V., Dawson A.E., Dziura B., et al. Assisted primary screening using the automated ThinPrep imaging system. Am. J. Clin. Pathol. 123 (2005) 281-287
23. In: Solomon D., and Nayar R. (Eds). The Bethesda System for Reporting Cervical Cytology: definitions, criteria, and explanatory notes. 2nd ed. (2004), Springer-Verlag, New York
24. Belinson J., Qiao Y.L., Pretorius R., et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol. Oncol. 83 (2001) 439-444
25. Schiffman M., Herrero R., Hildesheim A., et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283 (2000) 87-93
26. Mandelblatt J.S., Lawrence W.F., Womack S.M., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 (2002) 2372-2381
27. Bidus M.A., Maxwell G.L., Kulasingam S., et al. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet. Gynecol. 107 (2006) 997-1005
28. Davey D.D., Neal M.H., Wilbur D.C., Colgan T.J., Styer P.E., and Mody D.R. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in cervicovaginal cytology. Arch. Pathol. Lab. Med. 128 (2004) 1224-1229
29. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 1 (2003) 67-73
30. Federschneider J.M., Yuan L., Brodsky J., Breslin G., Betensky R.A., and Crum C.P. The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am. J. Obstet. Gynecol. 191 3 (2004) 757-761
31. Seme K., Fujs K., Kocjan B.J., and Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J. Virol. Methods 134 1-2 (2006) 252-256
32. de Cremoux P., Coste J., Sastre-Garau X., Thioux M., Bouillac C., and Labbe S. French Society of Clinical Cytology Study Group. Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. Am. J. Clin. Pathol. 120 4 (2003) 492-499